ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
29 avr. 2024 07h57 HE
|
ZyVersa Therapeutics
NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
18 avr. 2024 16h05 HE
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15 avr. 2024 08h30 HE
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08 avr. 2024 08h30 HE
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14 mars 2024 07h57 HE
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
08 mars 2024 13h36 HE
|
Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
14 févr. 2024 07h53 HE
|
ZyVersa Therapeutics
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
13 févr. 2024 08h30 HE
|
Lantheus Holdings, Inc.
Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ:...
Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discovery and Development
07 févr. 2024 11h30 HE
|
Alleo Labs
Alleo Labs, a biotechnology company based in San Francisco, publishes an article on the use of artificial intelligence in neuroscience drug discovery.
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07 févr. 2024 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...